Compare Futu Holdings Ltd (FUTU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs TG Therapeutics Inc — how do they compare? Futu Holdings Ltd trades at $113.73 (market cap $15.25B), while TG Therapeutics Inc trades at $55.15 (market cap $8.16B). The key difference: Futu Holdings Ltd is the larger of the two by market cap, and Futu Holdings Ltd pays a 2.39% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and TG Therapeutics Inc for 15 Days on average.
| FUTU | TGTX | |
|---|---|---|
Market Cap | $15.25B | $8.16B |
Volume | 812,567 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $199.04 | $59.06 |
52-Week Low | $89.76 | $26.94 |
Typical Hold Time | 34 Days | 15 Days |
Enterprise Value | $15.59B | $8.37B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings trades at $113.52, up 3.5% in the last session. The stock exhibits strong fundamentals with a P/E of 10.86 and net income margin of 42.92%, though technical indicators signal a bearish trend. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1 2026. The company's Moomoo platform continues expanding globally, with new partnerships and marketing initiatives driving user growth.
Outlook remains positive due to robust profitability and overseas expansion, but risks include ongoing securities class action lawsuits and competitive pressures. Analyst consensus is bullish with a 58.3% buy rating, projecting significant upside potential from current levels.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
